Deutsche Bank AG Raises Stock Holdings in CONMED Co. (NYSE:CNMD)

Deutsche Bank AG increased its position in shares of CONMED Co. (NYSE:CNMD - Free Report) by 47.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,261 shares of the company's stock after acquiring an additional 9,442 shares during the period. Deutsche Bank AG owned about 0.09% of CONMED worth $2,003,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Dean Capital Management grew its holdings in CONMED by 64.4% during the fourth quarter. Dean Capital Management now owns 25,575 shares of the company's stock valued at $1,750,000 after purchasing an additional 10,019 shares during the last quarter. Brevan Howard Capital Management LP raised its holdings in CONMED by 178.3% in the 4th quarter. Brevan Howard Capital Management LP now owns 12,740 shares of the company's stock worth $872,000 after acquiring an additional 8,162 shares during the period. Captrust Financial Advisors lifted its position in CONMED by 53.0% during the 4th quarter. Captrust Financial Advisors now owns 9,562 shares of the company's stock worth $654,000 after acquiring an additional 3,311 shares during the last quarter. Beverly Hills Private Wealth LLC lifted its position in CONMED by 4.7% during the 4th quarter. Beverly Hills Private Wealth LLC now owns 3,762 shares of the company's stock worth $257,000 after acquiring an additional 168 shares during the last quarter. Finally, AXA S.A. boosted its holdings in CONMED by 15.4% during the fourth quarter. AXA S.A. now owns 48,595 shares of the company's stock valued at $3,326,000 after acquiring an additional 6,500 shares during the period.

Insiders Place Their Bets

In related news, Director Charles Farkas sold 4,000 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $56.94, for a total value of $227,760.00. Following the completion of the transaction, the director now owns 16,346 shares of the company's stock, valued at $930,741.24. This represents a 19.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.10% of the company's stock.

CONMED Stock Up 0.9%

NYSE CNMD traded up $0.54 during trading on Thursday, hitting $57.61. The stock had a trading volume of 251,467 shares, compared to its average volume of 446,792. CONMED Co. has a 12 month low of $46.00 and a 12 month high of $78.58. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.06 and a current ratio of 2.30. The company's 50-day moving average price is $55.35 and its two-hundred day moving average price is $63.50. The company has a market capitalization of $1.78 billion, a PE ratio of 13.59, a P/E/G ratio of 1.83 and a beta of 1.19.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. The business had revenue of $321.26 million for the quarter, compared to the consensus estimate of $313.38 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. CONMED's quarterly revenue was up 2.9% on a year-over-year basis. As a group, sell-side analysts forecast that CONMED Co. will post 4.35 EPS for the current year.

CONMED Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 3rd. Investors of record on Friday, June 13th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date is Friday, June 13th. CONMED's dividend payout ratio is currently 21.05%.

Analyst Upgrades and Downgrades

CNMD has been the subject of a number of research reports. Needham & Company LLC reduced their price target on shares of CONMED from $91.00 to $61.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Stifel Nicolaus cut CONMED from a "buy" rating to a "hold" rating and cut their price target for the company from $75.00 to $55.00 in a report on Monday, April 28th. Wells Fargo & Company decreased their price objective on CONMED from $70.00 to $57.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. JPMorgan Chase & Co. cut their target price on CONMED from $70.00 to $58.00 and set a "neutral" rating for the company in a research note on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of CONMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $62.20.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.